Lipid Management in Statin-Intolerant Patients

Non-Statin Pharmacological Options

The American Heart Association recommends bile acid sequestrants and/or niacin as reasonable first-line alternatives for LDL-C lowering therapy in statin-intolerant patients, with ezetimibe, bempedoic acid, and PCSK9 inhibitors as additional options depending on the patient's specific lipid profile and cardiovascular risk (Level of Evidence: B) 1, 2, 3
Bile acid sequestrants are reasonable for LDL-C lowering in statin-intolerant patients (Level of Evidence: B) 4, 1
Niacin is reasonable for LDL-C lowering in statin-intolerant patients (Level of Evidence: B) and may be particularly beneficial for those with low HDL cholesterol or elevated Lp(a) 1, 5
Ezetimibe (10 mg daily) reduces LDL-C by 15-20% by inhibiting intestinal cholesterol absorption and has a side-effect profile similar to placebo, making it suitable for statin-intolerant patients 2
Bempedoic acid reduces LDL-C levels by 15-25% with low rates of muscle-related adverse effects, making it particularly valuable for statin-intolerant patients 2, 3
A combination product of bempedoic acid with ezetimibe can lower LDL-C levels by approximately 35% 3
PCSK9 inhibitors (alirocumab, evolocumab, inclisiran) are highly effective in statin-intolerant patients, reducing LDL-C by approximately 50% 3, 6
Fibrates (fenofibrate, gemfibrozil) should be considered for patients with triglycerides >500 mg/dL to prevent acute pancreatitis (Level of Evidence: C) 4, 7

For patients with elevated LDL-C, the American College of Cardiology recommends first attempting ezetimibe monotherapy (10 mg daily) 3
If there is an inadequate response to ezetimibe, adding bempedoic acid or considering bempedoic acid/ezetimibe fixed-dose combination is recommended 2, 8
For patients with elevated triglycerides (≥200 mg/dL), the American Heart Association recommends targeting non-HDL-C <130 mg/dL (<100 mg/dL for very high-risk patients) 7
Omega-3 fatty acids (fish oil capsules, 1g/day) may be reasonable for cardiovascular disease risk reduction in patients with elevated triglycerides 1, 7

The American Heart Association strongly recommends lifestyle modifications, including daily physical activity and weight management, for all patients (Level of Evidence: B) 4, 1
Dietary therapy should include reduced intake of saturated fats (<7% of total calories), trans fatty acids (<1% of total calories), and cholesterol (<200 mg/d) (Level of Evidence: B) 4, 1
A Mediterranean diet appears beneficial for lipid management 9

For patients with diabetes or metabolic disorders, the American Diabetes Association recommends considering ezetimibe as first-line therapy as it does not negatively impact glycemic control 8, 6
Bempedoic acid may help optimize both LDL-C therapy and glycemic parameters in patients with diabetes or metabolic disorders 8
For patients with very high cardiovascular risk, the American College of Cardiology recommends considering combination therapy immediately rather than sequential monotherapy to achieve LDL-C targets more rapidly 2, 8
Target LDL-C <70 mg/dL or even <55 mg/dL for secondary prevention in patients with very high cardiovascular risk 2, 3

The American Heart Association recommends obtaining baseline lipid profile before initiating therapy and reassessing lipid profile 4-8 weeks after initiating therapy and adjusting treatment as needed 4, 1, 2
Monitor for adverse effects specific to each medication (e.g., liver function with bempedoic acid, uric acid with niacin) 3